Top

Published in:

Open Access 03-10-2023 | Bevacizumab | Case Study

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial

Authors: Johannes Weller, Thomas Zeyen, Niklas Schäfer, Christina Schaub, Anna-Laura Potthoff, Joachim P. Steinbach, Peter Hau, Clemens Seidel, Roland Goldbrunner, Ghazaleh Tabatabai, Hartmut Vatter, Theophilos Tzaridis, Matthias Schneider, Ulrich Herrlinger

Published in: Journal of Neuro-Oncology | Issue 3/2023

Abstract

Purpose

The AVAglio trial reported a significant survival benefit for first line bevacizumab treatment in patients with IDH wildtype glioblastoma of the proneural gene expression subtype. We here aim to replicate these findings in an independent trial cohort.

Methods

We evaluate the treatment benefit of bevacizumab according to gene expression subtypes of pretreatment tumor samples (n = 123) in the GLARIUS trial (NCT00967330) for MGMT unmethylated glioblastoma patients with Kaplan-Meier analyses, log-rank tests and Cox regression models.

Results

Employing the Phillips classifier, bevacizumab conferred a significant PFS advantage in patients with proneural IDH wild-type tumors (10.4 vs. 6.0 months, p = 0.002), but no OS advantage (16.4 vs. 17.4 months, p = 0.6). Multivariable analysis adjusting for prognostic covariates confirmed the absence of a significant OS advantage from bevacizumab (hazard ratio, 1.05, 95% CI, 0.42 to 2.64; p = 0.14). Further, there was no interaction between the proneural subtype and treatment arm (p = 0.15). These results were confirmed in analyses of tumor subgroups according to the Verhaak classifier.

Conclusion

In contrast to AVAglio, glioblastoma gene expression subgroups were not associated with a differential OS benefit from first-line bevacizumab in the GLARIUS trial.

Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and european Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22:1073–1113. https://doi.org/10.1093/neuonc/noaa106CrossRefPubMedPubMedCentral

Brandes AA, Tosoni A, Franceschi E et al (2008) Glioblastoma in adults. Crit Rev Oncol Hematol 67:139–152. https://doi.org/10.1016/j.critrevonc.2008.02.005CrossRefPubMed

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345CrossRefPubMed

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573CrossRefPubMedPubMedCentral

Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173. https://doi.org/10.1016/j.ccr.2006.02.019CrossRefPubMed

Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. https://doi.org/10.1016/j.ccr.2009.12.020CrossRefPubMedPubMedCentral

Sandmann T, Bourgon R, Garcia J et al (2015) Patients with Proneural Glioblastoma May derive overall Survival Benefit from the addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: retrospective analysis of the AVAglio Trial. J Clin Oncol 33:2735–2744. https://doi.org/10.1200/JCO.2015.61.5005CrossRefPubMedPubMedCentral

Mayer TM (2015) Can we predict Bevacizumab Responders in patients with glioblastoma? J Clin Oncol 33:2721–2722. https://doi.org/10.1200/JCO.2015.62.3637CrossRefPubMed

Seidel C, Kortmann R-D (2016) [Survival benefit from the addition of bevacizumab to first-line radiochemotherapy for the treatment of proneural glioblastoma?]. Strahlenther Onkol 192:65–66. https://doi.org/10.1007/s00066-015-0922-3CrossRefPubMed

10.

Kessler T (2016) Predicting glioblastoma response to bevacizumab through marker profiling? Neuro Oncol 18:149–150. https://doi.org/10.1093/neuonc/nov320CrossRefPubMedPubMedCentral

11.

Herrlinger U, Schäfer N, Steinbach JP et al (2016) Bevacizumab Plus Irinotecan Versus Temozolomide in newly diagnosed O6-Methylguanine-DNA methyltransferase nonmethylated Glioblastoma: the Randomized GLARIUS Trial. J Clin Oncol 34:1611–1619. https://doi.org/10.1200/JCO.2015.63.4691CrossRefPubMed

12.

Johnson RM, Phillips HS, Bais C et al (2020) Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. Neuro Oncol 22:1742–1756. https://doi.org/10.1093/neuonc/noaa157CrossRefPubMedPubMedCentral

13.

Neftel C, Laffy J, Filbin MG et al (2019) An integrative model of Cellular States, plasticity, and Genetics for Glioblastoma. Cell 178:835–849e21. https://doi.org/10.1016/j.cell.2019.06.024CrossRefPubMedPubMedCentral

14.

Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 377:1954–1963. https://doi.org/10.1056/NEJMoa1707358CrossRefPubMed

15.

Pellerino A, Bruno F, Soffietti R, Rudà R (2023) Antiangiogenic therapy for malignant brain tumors: does it still Matter? Curr Oncol Rep 25:777–785. https://doi.org/10.1007/s11912-023-01417-1CrossRefPubMedPubMedCentral

16.

Sulman EP, Won M, Blumenthal DT et al (2013) Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). JCO 31:LBA2010–LBA2010. https://doi.org/10.1200/jco.2013.31.18_suppl.lba2010CrossRef

17.

Kessler T, Schrimpf D, Doerner L et al (2023) Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial. Clin Cancer Res CCR. https://doi.org/10.1158/1078-0432.CCR-23-0926. -23-0926CrossRef

Title: The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
Authors: Johannes Weller
Thomas Zeyen
Niklas Schäfer
Christina Schaub
Anna-Laura Potthoff
Joachim P. Steinbach
Peter Hau
Clemens Seidel
Roland Goldbrunner
Ghazaleh Tabatabai
Hartmut Vatter
Theophilos Tzaridis
Matthias Schneider
Ulrich Herrlinger
Publication date: 03-10-2023
Publisher: Springer US
Keywords: Bevacizumab
Glioblastoma
Glioblastoma
Glioblastoma
Published in: Journal of Neuro-Oncology / Issue 3/2023
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04470-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

Age and sex disparities in Latin-American adults with gliomas: a systematic review and meta-analysis

Correction to: MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44

Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy

Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors

Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients